ImmuPharma (GB:IMM) has released an update.
ImmuPharma PLC, a biopharmaceutical company focusing on peptide-based therapeutics, has announced its Annual General Meeting (AGM) to be held on June 28, 2024. Shareholders are informed that the AGM details and Annual Report for 2023 are available on the company’s website. The company specializes in developing treatments for autoimmune diseases, with its leading program, P140, showing promise for Lupus and other autoimmune disorders.
For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.